AXO-1801

N/A

Report date: 2024/11/15 10:00:10
NME

Base Information

Drug NameAXO-1801
Drug Alias NameAXO-1801AX-0085
ClassificationSmall molecules
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsIndoleamine 2,3-dioxygenase inhibitorsProgrammed death-ligand 1 blockers
TargetsAXL receptor tyrosine kinaseIndoleamine 2,3-dioxygenaseProgrammed death-ligand 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAxceso Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAxceso Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A